Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890661 | 0.79 | LRRK2 (0.50) | LRRK2DYRK1AKDM4ERXFP1CCNA2 | |
| SCHEMBL13020443 | 0.78 | KDM4E (0.32) | LRRK2KDM4E | |
| SCHEMBL13058597 | 0.74 | SQOR (0.40) | — | |
| SCHEMBL12186825 | 0.74 | LRRK2 (0.47) | LRRK2DYRK1AKDM4ERXFP1CCNA2 | |
| SCHEMBL13828431 | 0.71 | LRRK2 (0.45) | LRRK2DYRK1AKDM4ECCNA2CDK2 | |
| SCHEMBL22030038 | 0.71 | ALDH1A1 (0.40) | KDM4ECCNA2CDK2CCNA1 | |
| SCHEMBL24714020 | 0.69 | PI4KA (0.36) | KDM4E | |
| SCHEMBL12957026 | 0.69 | LRRK2 (0.43) | LRRK2DYRK1AKDM4ERXFP1CCNA2 | |
| SCHEMBL16783455 | 0.69 | DYRK1A (0.49) | LRRK2DYRK1AKDM4ERXFP1CCNA2 | |
| SCHEMBL31265625 | 0.69 | LRRK2 (0.43) | LRRK2DYRK1AKDM4ERXFP1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840498-B2 | Substituted quinazolin-4-one derivatives | NOVARTIS AG (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9499523-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150361071-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-9181221-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LRRK2 613/4885DYRK1A 1201/4885KDM4E 2229/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LRRK2 613/4885DYRK1A 1201/4885KDM4E 2229/4885 |
| US-20150361071-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, PIK3CD | LRRK2 467/4885DYRK1A 477/4885KDM4E 3419/4885 |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LRRK2 613/4885DYRK1A 1201/4885KDM4E 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.